The Australian Securities and Investments Commission has won an interim travel ban against the CEO of software company Dubber Corporation and its external solicitor in Melbourne, with the regulator saying it suspects misuse of term deposit funds.
Ashurst has bolstered its disputes team by reclaiming a senior commercial litigation partner from Clifford Chance, who has predicted more defence firms will cross over and represent plaintiffs in class actions.
Hells Angels has asked the High Court to reinstate an award of $78,000 for online marketplace Redbubble’s infringement of its trade marks, after the Full Court found it was owed just $100 in nominal damages.
Investors in an apartment development in Melbourne have brought a class action against the responsible managers for two managed investment schemes, alleging their funds were misused.
Indian generics company Sun Pharma has taken Otsuka Pharmaceutical to court, alleging an extension for the patent for an injectable form of the Japanese drug maker’s blockbuster antipsychotic Abilify was wrongly granted and should be invalidated.
Google has criticised two competition class actions which piggyback on claims brought by Fornite developer Epic Games as “opportunistic”, but counsel for the class actions told a court the suits on behalf of more than 15 million group members were in the public interest.
A judge has set aside subpoenas in a class action against Mercedes-Benz over alleged emissions cheating seeking material to identify group members and clarify the composition of the class, finding they were not issued for a legitimate forensic purpose.
The AFL has scored a small victory in concussion litigation brought by players, winning an order temporarily halting a case by former Western Bulldogs player Liam Picken.
A client of EY has sued a former partner at the firm, accusing them of collecting $700,000 in secret payments as part of a tax loss scheme.
The Australian unit of drug giant Mylan has triumphed in a dispute with Australian Taxation Office, with a judge finding the ATO’s assessment for 2020 was “excessive” with respect to interest on loans to fund Mylan’s $1.2 billion acquisition of generic drug maker Alphapharm.